A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety

Summary

This is a multicenter, randomized, open, parallel group, active-controlled study. The study period is 25 to 26 weeks, including screening period of 1-2 weeks and treatment period of 24 weeks.

Timeline

Start

2015-06-19

Primary completion

2016-08-12

Completion

2016-08-12

Drugs

Indications